(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.79%.
Dyne Therapeutics's earnings in 2026 is -$604,917,000.On average, 18 Wall Street analysts forecast DYN's earnings for 2026 to be -$698,541,121, with the lowest DYN earnings forecast at -$727,211,326, and the highest DYN earnings forecast at -$617,814,817. On average, 17 Wall Street analysts forecast DYN's earnings for 2027 to be -$654,767,526, with the lowest DYN earnings forecast at -$855,758,783, and the highest DYN earnings forecast at -$541,079,856.
In 2028, DYN is forecast to generate -$524,552,326 in earnings, with the lowest earnings forecast at -$978,797,063 and the highest earnings forecast at -$147,567,233.